| Date | Title | Description | Source |
| 03.04.2024 | Ascletis Announces Strategic Decisions on FXR agonist ASC42 | HANGZHOU, China and SHAOXING, China, April 3, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, ... | en.prnasia... |
| 11.03.2024 | Ascletis Announces Poster Presentation of Phase II Study Fin... | HANGZHOU and SHAOXING, China, March 11, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "... | en.prnasia... |
| 24.01.2024 | Ascletis Announces Dosing of the First Patient in Phase III ... | HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "... | en.prnasia... |
| 23.01.2024 | Gannex's Strategic Partner Sagimet Biosciences Announces Pos... | Denifanstat achieved statistically significant results on primary and multiple secondary endpoints i... | en.prnasia... |
| 05.12.2023 | Ascletis Announces Initiation of Phase III Clinical Trial of... | --The Phase III clinical trial of ASC40 for moderate to severe acne vulgaris will enroll 480 subject... | en.prnasia... |
| 13.11.2023 | Ascletis Announces Poster Presentations at AASLD Annual Meet... | HANGZHOU and SHAOXING, China, Nov. 13, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "... | en.prnasia... |
| 09.11.2023 | Dr. Jinzi J. Wu Presents at the 10th International Workshop ... | HANGZHOU and SHAOXING, China, Nov. 9, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "A... | en.prnasia... |
| 06.11.2023 | Gannex Published Phase I Data of ASC42, a Novel Farnesoid X ... | SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned ... | en.prnasia... |
| 11.10.2023 | Ascletis Announces Poster Presentation of Phase II Study Top... | HANGZHOU and SHAOXING, China, Oct. 11, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "A... | en.prnasia... |
| 29.09.2023 | Ascletis Announces Positive Interim Data from the Phase IIb ... | HANGZHOU and SHAOXING, China, Sept. 29, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "... | en.prnasia... |
| 26.09.2023 | Ascletis Announces Completion of Enrollment of 120 Patients ... | --Based on prespecified interim analysis condition, 120 patients are likely to lead sufficient event... | en.prnasia... |
| 05.09.2023 | Ascletis to Participate in the Upcoming Morgan Stanley 21st ... | HANGZHOU and SHAOXING, China, Sept. 5, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "... | en.prnasia... |
| 25.07.2023 | Clinical Results of ASC22 (Envafolimab) in Combination with ... | HANGZHOU and SHAOXING, China, July 25, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "... | en.prnasia... |
| 20.07.2023 | Gannex Announces the Completion of Patient Enrollment for Ph... | -- Gannex is expected to release topline data of the Phase II clinical trial by the end of 2023
SHAN... | en.prnasia... |
| 26.06.2023 | Ascletis Announces Poster Presentation of Phase II Study of ... | HANGZHOU and SHAOXING, China, June 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "A... | en.prnasia... |
| 08.05.2023 | Ascletis Announces China NMPA Approval of Conducting a Phase... | --Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there i... | en.prnasia... |
| 02.05.2023 | Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral ... | HANGZHOU and SHAOXING, China, May 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "As... | en.prnasia... |
| 27.02.2023 | Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Liste... | HANGZHOU and SHAOXING, China, Feb. 27, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "... | en.prnasia... |
| 21.02.2023 | Ascletis Presented Positive Phase I Clinical Data for Broad-... | --At the dosage of 800 mg ASC10, twice daily (BID), the exposure of the active drug, ASC10-A, is com... | en.prnasia... |
| 16.02.2023 | Oral Presentation at APASL Annual Meeting 2023 Demonstrates ... | HANGZHOU and SHAOXING, China, Feb. 16, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "A... | en.prnasia... |
| 31.01.2023 | Ascletis Announces U.S. FDA Approval of Conducting a Phase I... | --Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there i... | en.prnasia... |
| 31.01.2023 | Ascletis Announces U.S. FDA Approval of Conducting a Phase I... | --Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there i... | einpresswi... |
| 26.01.2023 | Ascletis Announces IND Approval of Oral Viral Polymerase Inh... | --Preclinical studies show that ASC10-A, the active metabolite of double prodrug ASC10, has potent a... | en.prnasia... |
| 17.01.2023 | Ascletis Announces Entering into a Supply Agreement of Riton... | HANGZHOU and SHAOXING, China, Jan. 17, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "... | en.prnasia... |
| 16.01.2023 | Ascletis Announces Dosing of 4 Healthy Subjects of the First... | --The multiple-dose escalation Phase I clinical trial is expected to enroll 72 healthy subjects, and... | en.prnasia... |
| 02.01.2023 | Ascletis Believes that the Complaints Made by Viking Therape... | HANGZHOU and SHAOXING, China, Jan. 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "A... | einpresswi... |
| 02.01.2023 | Ascletis Believes that the Complaints Made by Viking Therape... | HANGZHOU and SHAOXING, China, Jan. 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "A... | en.prnasia... |
| 21.12.2022 | Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progr... | HANGZHOU and SHAOXING, China, Dec. 21, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II c... | en.prnasia... |
| 21.12.2022 | Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progr... | HANGZHOU and SHAOXING, China, Dec. 20, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II c... | einpresswi... |
| 19.12.2022 | Ascletis Announces Notice of Issuance of the U.S. Patent for... | --The issue date of the patent will be January 3, 2023 by the United States Patent and Trademark Off... | en.prnasia... |
| 12.12.2022 | Ascletis Announces Positive Phase I Clinical Results of Oral... | --The exposure of active drug ASC10-A after twice daily dosing 800 mg double prodrug ASC10 in Chines... | en.prnasia... |
| 07.12.2022 | Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC... | --The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal... | en.prnasia... |
| 30.11.2022 | Ascletis Announces Completion of 180 Patient Enrollment for ... | --To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled pat... | en.prnasia... |
| 29.11.2022 | Ascletis Announces IND Filing of Oral 3CLpro Inhibitor ASC11... | HANGZHOU, China and SHAOXING, China, Nov. 29, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672,... | en.prnasia... |
| 23.11.2022 | Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC... | --The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and mu... | en.prnasia... |
| 17.11.2022 | Ascletis Announces IND Approval of Oral PD-L1 Small Molecule... | --While the ASC61 Phase I study is ongoing in the U.S., the Investigational New Drug (IND) approval ... | en.prnasia... |
| 16.11.2022 | Ascletis Announces IND Approval of Viral Polymerase Inhibito... | --Based on available data, ASC10 at the dosage of 800 mg twice daily was approved by the U.S. Food a... | einpresswi... |
| 16.11.2022 | Ascletis Announces IND Approval of Viral Polymerase Inhibito... | --Based on available data, ASC10 at the dosage of 800 mg twice daily was approved by the U.S. Food a... | en.prnasia... |
| 07.11.2022 | Ascletis Announces Poster Presentation of Phase I, Single-Do... | HANGZHOU and SHAOXING, China, Nov. 7, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "As... | en.prnasia... |
| 02.11.2022 | Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ... | -- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like... | en.prnasia... |
| 02.11.2022 | Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ... | -- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like... | einpresswi... |
| 26.10.2022 | Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 f... | --ASC10 has two indications: monkeypox and SARS-CoV-2 virus infections. The Investigational New Drug... | en.prnasia... |
| 10.10.2022 | Ascletis Announces Dosing of 24 Healthy Subjects of the Firs... | --The multiple-dose escalation Phase I clinical trial will enroll 72 healthy subjects including 60 s... | en.prnasia... |
| 05.10.2022 | Ascletis Announces Dosing of the First Patient in Phase II C... | -- ASC41 is ranking first in China and third in the world in terms of clinical progress as a thyroid... | en.prnasia... |
| 28.09.2022 | Ascletis Announces Dosing of the First Patient in the Phase ... | -- After the pre-Phase III clinical trial meeting with Center for Drug Evaluation (CDE) of China Nat... | en.prnasia... |
| 15.09.2022 | Shanghai Public Health Clinical Center Completed Patient Enr... | HANGZHOU and SHAOXING, China, Sept. 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "... | en.prnasia... |
| 22.08.2022 | Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10... | -- Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibi... | en.prnasia... |
| 16.08.2022 | Gannex Announces First Subject Dosed in the U.S. Drug-Drug I... | -- Enrollment of the total 12 subjects is expected to be completed in August 2022
-- The DDI study o... | en.prnasia... |
| 16.08.2022 | Gannex Announces First Subject Dosed in the U.S. Drug-Drug I... | -- Enrollment of the total 12 subjects is expected to be completed in August 2022
-- The DDI study o... | einpresswi... |
| 08.08.2022 | Ascletis Announces First Patient Dosed in the U.S. Phase I C... | --ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant... | en.prnasia... |
| 04.08.2022 | Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 f... | HANGZHOU, China and SHAOXING, China, Aug. 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, ... | en.prnasia... |
| 03.08.2022 | Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC1... | -- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active ... | en.prnasia... |
| 06.07.2022 | Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Dr... | -- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and A... | en.prnasia... |
| 04.07.2022 | Shanghai Public Health Clinical Center Completed the First P... | HANGZHOU and SHAOXING, China, July 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "A... | en.prnasia... |
| 28.06.2022 | Ascletis Announced First Subject Dosed in the Phase II Clini... | -- The Phase II clinical study in China is currently expected to be completed in early 2023 with an ... | en.prnasia... |
| 27.06.2022 | Ascletis' Subcutaneous PD-L1 Antibody ASC22 Demonstrated Pot... | --Ascletis presented Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 for funct... | en.prnasia... |
| 16.06.2022 | Ascletis Announces Oral Presentation on Updates from Phase I... | - The updates of ASC22 Phase IIb study will be presented at the oral session during the Internationa... | en.prnasia... |
| 16.06.2022 | Ascletis Announces Oral Presentation on Updates from Phase I... | - The updates of ASC22 Phase IIb study will be presented at the oral session during the Internationa... | en.prnasia... |
| 13.06.2022 | Ascletis Announces Appointment of Mr. John P. Gargiulo, Form... | HANGZHOU, China and SHAOXING, China, June 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672,... | en.prnasia... |
| 08.06.2022 | Gannex Announces U.S. FDA Clearance of Clinical Trial on FXR... | -- ASC42 has completed Phase I trials in the U.S. and China. This approval from U.S. FDA enables Gan... | en.prnasia... |
| 16.05.2022 | Ascletis (1672.HK) Included in MSCI China Small Cap Index | HANGZHOU and SHAOXING, China, May 16, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "A... | en.prnasia... |
| 11.05.2022 | Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) ... | HANGZHOU, China and SHAOXING, China, May 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, ... | en.prnasia... |
| 19.04.2022 | Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Poten... | - In antiviral cellular assays, antiviral potency (EC90) of ASC11 is 31-fold of that of Nirmatrelvir... | en.prnasia... |
| 13.04.2022 | Ascletis Announces Cooperation with China Meheco Internation... | HANGZHOU, China and SHAOXING, China, April 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672... | en.prnasia... |
| 10.04.2022 | Gannex Announces First Patient Dosed in Phase II Clinical Tr... | -- Gannex is expected to complete the Phase II trial in 100 patients by the end of 2022.
-- Gannex i... | en.prnasia... |
| 06.04.2022 | Ascletis Announces China IND Approval of Its Second FASN Inh... | HANGZHOU, China and SHAOXING, China, April 6, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: ... | en.prnasia... |
| 04.04.2022 | Ascletis Announces Completion of First Sale of Its Ritonavir... | HANGZHOU, China and SHAOXING, China, April 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)... | en.prnasia... |
| 03.04.2022 | Ascletis Announces Submission of Marketing Authorization App... | HANGZHOU and SHAOXING, China, April 3, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today ... | en.prnasia... |
| 30.03.2022 | Ascletis Announces Completion of Patient Enrollment in Phase... | --Compared to the placebo cohort, both 10 mg and 15 mg ASC42 cohorts are safe and well tolerated to ... | en.prnasia... |
| 27.03.2022 | Ascletis Announces the Latest Results of the Preclinical Stu... | HANGZHOU, China and SHAOXING, China, March 27, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672)... | en.prnasia... |
| 15.03.2022 | Business Update on ASC10, an Oral Double Prodrug against COV... | HANGZHOU and SHAOXING, China, March 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today... | en.prnasia... |
| 13.03.2022 | Ascletis Announces Further Expansion of Ritonavir Oral Table... | HANGZHOU, China and SHAOXING, China, March 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, ... | en.prnasia... |
| 01.03.2022 | Ascletis Announces Submission of Marketing Authorization App... | -- Ritonavir marketing authorization applications have been submitted to Spain, Portugal, Italy, Bel... | en.prnasia... |
| 14.02.2022 | Shanghai Public Health Clinical Center Initiated Functional ... | HANGZHOU, China and SHAOXING, China, Feb. 14, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)... | en.prnasia... |
| 14.02.2022 | Shanghai Public Health Clinical Center Initiated Functional ... | HANGZHOU, China and SHAOXING, China, Feb. 14, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)... | marketscre... |
| 13.02.2022 | Ascletis Announces Submission of Marketing Authorization App... | HANGZHOU, China and SHAOXING, China, Feb. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)... | marketscre... |
| 13.02.2022 | Ascletis Announces Submission of Marketing Authorization App... | HANGZHOU, China and SHAOXING, China, Feb. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)... | en.prnasia... |
| 07.02.2022 | Ascletis Announces Positive Data of Oral Double Prodrug ASC1... | ASC10-A demonstrated strong in vitro antiviral activity against multiple SARS-CoV-2 virus variants i... | en.prnasia... |
| 07.02.2022 | Ascletis Announces Positive Data of Oral Double Prodrug ASC1... | ASC10-A demonstrated strong in vitro antiviral activity against multiple SARS-CoV-2 virus variants i... | marketscre... |
| 06.02.2022 | Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Mol... | The objectives of the U.S. Phase I trial are to find a recommended Phase II dose and obtain prelimin... | marketscre... |
| 06.02.2022 | Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Mol... | The objectives of the U.S. Phase I trial are to find a recommended Phase II dose and obtain prelimin... | en.prnasia... |
| 26.01.2022 | Ascletis Announces IND Filing of Its Second FASN Inhibitor A... | HANGZHOU, China and SHAOXING, China, Jan. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: ... | en.prnasia... |
| 26.01.2022 | Ascletis Announces IND Filing of Its Second FASN Inhibitor A... | HANGZHOU, China and SHAOXING, China, Jan. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: ... | marketscre... |
| 23.01.2022 | Ascletis Announces First Patient Dosed in the Phase III Clin... | HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) t... | en.prnasia... |
| 23.01.2022 | Ascletis Announces First Patient Dosed in the Phase III Clin... | HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) t... | marketscre... |
| 18.01.2022 | Ascletis Announces Signing of Ritonavir Tablet Purchase Agre... | HANGZHOU and SHAOXING, China, Jan. 18, 2022 /PRNewswire/ -- Ascletis Pharma Inc. ("Ascletis&quo... | en.prnasia... |
| 18.01.2022 | Ascletis Announces Signing of Ritonavir Tablet Purchase Agre... | HANGZHOU and SHAOXING, China, Jan. 18, 2022 /PRNewswire/ -- Ascletis Pharma Inc. ("Ascletis&quo... | marketscre... |
| 17.01.2022 | Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab),... | -- Estimated 1.59 million chronic hepatitis B (CHB) patients in the U.S.
-- Interim results of the P... | en.prnasia... |
| 13.01.2022 | Ascletis Announces First Patient Dosed in the Phase II Clini... | HANGZHOU and SHAOXING, China, Jan. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today ... | marketscre... |
| 13.01.2022 | Ascletis Announces First Patient Dosed in the Phase II Clini... | HANGZHOU and SHAOXING, China, Jan. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today ... | en.prnasia... |
| 11.01.2022 | Ascletis Announces First Patient Dosed in the Phase II Clini... | HANGZHOU, China and SHAOXING, China, Jan. 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)... | marketscre... |
| 11.01.2022 | Ascletis Announces First Patient Dosed in the Phase II Clini... | HANGZHOU, China and SHAOXING, China, Jan. 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)... | en.prnasia... |
| 10.01.2022 | Ascletis Announces U.S. IND Filing for In-House Developed Or... | HANGZHOU, China and SHAOXING, China, Jan. 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)... | en.prnasia... |
| 10.01.2022 | Ascletis Announces U.S. IND Filing for In-House Developed Or... | HANGZHOU, China and SHAOXING, China, Jan. 9, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) ... | marketscre... |
| 04.01.2022 | Gannex Announces Completion of the U.S. Phase I Trial of ASC... | ASC43F was safe and well tolerated in healthy subjects with no clinically significant study drug rel... | marketscre... |
| 04.01.2022 | Gannex Announces Completion of the U.S. Phase I Trial of ASC... | ASC43F was safe and well tolerated in healthy subjects with no clinically significant study drug rel... | en.prnasia... |
| 08.11.2021 | Ascletis and Suzhou Alphamab Expand their Partnership into W... | HANGZHOU, China and SHAOXING, China and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Ascletis Pharma ... | en.prnasia... |
| 01.11.2021 | Gannex Announces U.S. IND Approval of ASC43F, a First-in-Cla... | SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis P... | en.prnasia... |
| 13.10.2021 | Gannex Announces Clinical and Preclinical Data of Four NASH ... | SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis ... | en.prnasia... |
| 12.10.2021 | Ascletis Announces Results of the Phase IIa trial of ASC22 (... | HANGZHOU and SHAOXING, China, Oct. 12, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announ... | en.prnasia... |
